首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

导出 OA

翻译打印收藏纠错

第一作者： Alfredo,Perales-Puchalt

第一单位： Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.

作者： Alfredo,Perales-Puchalt ^[1] ; Nikolaos,Svoronos ^[1] ; Melanie R,Rutkowski ^[1] ; Michael J,Allegrezza ^[1] ; Amelia J,Tesone ^[1] ; Kyle K,Payne ^[1] ; Jayamanna,Wickramasinghe ^[2] ; Jenny M,Nguyen ^[1] ; Shane W,O'Brien ^[3] ; Kiranmai,Gumireddy ^[1] ; Qihong,Huang ^[1] ; Mark G,Cadungog ^[4] ; Denise C,Connolly ^[3] ; Julia,Tchou ^[5] ; Tyler J,Curiel ^[6] ; Jose R,Conejo-Garcia ^[7]

作者单位： Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania. ^[1] Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania. ^[2] Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. ^[3] Helen F. Graham Cancer Center, Christiana Care Health System, Newark, Delaware. ^[4] Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania. ^[5] Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas. ^[6] Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania. jrconejo@Wistar.org. ^[7]